<small id='rv7yz'></small><noframes id='rv7yz'>

  • <tfoot id='rv7yz'></tfoot>

      <legend id='rv7yz'><style id='rv7yz'><dir id='rv7yz'><q id='rv7yz'></q></dir></style></legend>
      <i id='rv7yz'><tr id='rv7yz'><dt id='rv7yz'><q id='rv7yz'><span id='rv7yz'><b id='rv7yz'><form id='rv7yz'><ins id='rv7yz'></ins><ul id='rv7yz'></ul><sub id='rv7yz'></sub></form><legend id='rv7yz'></legend><bdo id='rv7yz'><pre id='rv7yz'><center id='rv7yz'></center></pre></bdo></b><th id='rv7yz'></th></span></q></dt></tr></i><div id='rv7yz'><tfoot id='rv7yz'></tfoot><dl id='rv7yz'><fieldset id='rv7yz'></fieldset></dl></div>

          <bdo id='rv7yz'></bdo><ul id='rv7yz'></ul>

        1. Pipeline of New Products

          Products Currently in Development
          Status of Product
          Immune Globulin Intravenous (Human), Caprylate/Chromatography Purified and 20 nm virus filtration
          Human Antithrombin III (concentration)
          Human coagulation factor IX
          Human Cytomegalovirus Immunoglobulin
          Human Fibrin Sealant
          Treatment for original immunoglobulin deficiency; secondary immunoglobulin deficiency and auto-immune deficiency diseases.
          Treatment for (1) hereditary antithrombin III deficiency in connection with surgical or obstetrical procedures and (2) thromboembolism.
          Prevention and control of bleeding in patients who suffer from hemophilia B.
          Prophylaxis and treatment of CMV infection, especially for the prevention of active virus replication for patients in immunosuppression, such as organ transplantation patients.
          Adjunct to hemostasis on patients undergoing surgery in case that traditional surgical techniques (such as suture, ligature or cautery) are ineffective or impractical.
          Obtained approval for clinical trial by the CFDA.
          Obtained approval for clinical trial by the CFDA. Designing clinical trial program.
          Completed the clinical trial and preparing documentation for the registration purpose.
          Obtained approval for clinical trial by the CFDA. In the process of collecting Cytomegalovirus specialty plasma.
          Obtained approval for clinical trial by the CFDA.

          Forward-Looking Statement

          This page may include forward-looking statements made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable as of today, those statements are subject to risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

          The company does not assume any obligation to update any forward-looking statements as a result of new information, future events, changes in market conditions or otherwise, except as required by law. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in China Biologic's 2014 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

          No Duty to Update

          The contained in this chart was current as of June 11, 2018. While this pipeline chart remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, investors should not rely upon the information as current or accurate after June 11, 2018.

          The chart reflects China Biologic's pipeline of new products as of June 11, 2018.

          © 2018 China Biologic Products Holdings, Inc. All Rights Reserved.           京ICP备18053264号